INHIBITOR OF p38 MAP KINASE
US-2015232450-A1 · Aug 20, 2015 · US
Kinase inhibitors
US9790174B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9790174-B2 |
| Application number | US-201615261174-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 9, 2016 |
| Priority date | Apr 2, 2013 |
| Publication date | Oct 17, 2017 |
| Grant date | Oct 17, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
There are provided compounds of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy. 2. A compound of formula IIb, as claimed in claim 1 , wherein LG 1 represents phenoxy.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for immunological or allergic disorders · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antihypertensives · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9790174B2 cover?
- There are provided compounds of formula IIb, wherein LG 1 represents imidazolyl, chloro or aryloxy, which compounds are useful in the preparation of compounds that have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinas…
- Who is the assignee on this patent?
- Respivert Ltd, Topivert Pharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D239/47. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).